



2021 American Epilepsy Society (AES) Annual Meeting (Chicago, IL): Eisai Inc. Sponsored Posters

Please see the Eisai Inc. sponsored posters presented at the 2021 American Epilepsy Society (AES) annual meeting listed below and refer to the Congress Links section available on our Medical Information website which may include additional information.

PERAMPANEL

1. Renfroe JB, Rozentals G, Filippov G, et al. Interim Safety and Efficacy Data of Adjunctive Perampanel in Pediatric Patients (Aged ≥ 1 to < 24 Months) with Epilepsy in Study 238 by Age. Poster presented at: American Epilepsy Society (AES) Annual Meeting; December 3-7, 2021; Chicago, IL.
2. Alsaadi T, Toledo M, Loro FA, et al. Real-World Experience of Perampanel Monotherapy in Epilepsy Patients with Focal-Onset and Generalized-Onset Seizures. Poster presented at: American Epilepsy Society (AES) Annual Meeting; December 3-7, 2021; Chicago, IL.
3. Auvin S, Garcia-Ron A, Datta A, et al. Perampanel for the Treatment of Pediatric Patients in Clinical Practice by Age Category. Poster presented at: American Epilepsy Society (AES) Annual Meeting; December 3-7, 2021; Chicago, IL.
4. Bonanni P, Di Bonaventura C, D'Souza W, et al. Perampanel for the Treatment of Patients with Lennox-Gastaut Syndrome in Clinical Practice. Poster presented at: American Epilepsy Society (AES) Annual Meeting; December 3-7, 2021; Chicago, IL.
5. Chiang H-I, Rocamora R, Castillo A, et al. Perampanel for the Treatment of Patients with Myoclonic Seizures in Clinical Practice. Poster presented at: American Epilepsy Society (AES) Annual Meeting; December 3-7, 2021; Chicago, IL.
6. Chinvarun Y, Ho C-J, Odintsova G, et al. Perampanel for the Treatment of Focal-Onset and Generalized-Onset Seizures in Patients with Post-Traumatic Brain Injury Etiology: Evidence from Clinical Practice. Poster presented at: American Epilepsy Society (AES) Annual Meeting; December 3-7, 2021; Chicago, IL.
7. Coppola A, Izumoto S, Rodríguez-Osorio X, et al. Clinical Practice Evidence for Perampanel in Epilepsy Patients with Tumor Etiology. Poster presented at: American Epilepsy Society (AES) Annual Meeting; December 3-7, 2021; Chicago, IL.

8. De Liso P, Wu T, Jacobs J, et al. Perampanel for the Treatment of Epilepsy Patients with Intellectual Disability in Clinical Practice. Poster presented at: American Epilepsy Society (AES) Annual Meeting; December 3-7, 2021; Chicago, IL.
9. Delgado RT, Morillo L, Vlasov P, et al. Real-World Evidence on the Use of Perampanel for the Treatment of Epilepsy Patients with Vascular Etiology. Poster presented at: American Epilepsy Society (AES) Annual Meeting; December 3-7, 2021; Chicago, IL.
10. Gil-López FJ, Shankar R, Yamamoto T, et al. Effectiveness, Safety and Tolerability of Perampanel in Adolescents with Focal-Onset and Generalized-Onset Seizures: Evidence from Clinical Practice. Poster presented at: American Epilepsy Society (AES) Annual Meeting; December 3-7, 2021; Chicago, IL.
11. Inaji M, McMurray R, Rohracher A, et al. The Use of Perampanel in Elderly Epilepsy Patients: Pooled Analysis of Real-World Studies. Poster presented at: American Epilepsy Society (AES) Annual Meeting; December 3-7, 2021; Chicago, IL.
12. Santamarina E, Abril-Jaramillo J, Rodriguez-Osorio X, et al. Perampanel as Early Add-on Therapy for Epilepsy Patients with Focal-onset and Generalized-Onset Seizures Treated in Clinical Practice. Poster presented at: American Epilepsy Society (AES) Annual Meeting; December 3-7, 2021; Chicago, IL.
13. Strzelczyk A, Wehner T, Deleo F, et al. Pooled Analysis of Adult Epilepsy Patients Treated with Perampanel in Everyday Clinical Practice. Poster presented at: American Epilepsy Society (AES) Annual Meeting; December 3-7, 2021; Chicago, IL.
14. Trinkka E, Mohanraj R, Maeda T, et al. Perampanel for the Treatment of Patients with Idiopathic Generalized Epilepsy in Clinical Practice. Poster presented at: American Epilepsy Society (AES) Annual Meeting; December 3-7, 2021; Chicago, IL.
15. Moseley BD, Wright J, Gupta S, et al. Real-World Impact of Perampanel Use Among Patients Diagnosed with Epilepsy in the United States. Poster presented at: American Epilepsy Society (AES) Annual Meeting; December 3-7, 2021; Chicago, IL.
16. Segal E, Aguilera-Albesa S, Filippov G, et al. Design of Study 236: A Phase II, Multicenter, Open-Label, Single-Arm Study of Adjunctive Perampanel in Patients (Aged 1 Month to <18 Years) with Childhood Epilepsy. Poster presented at: American Epilepsy Society (AES) Annual Meeting; December 3-7, 2021; Chicago, IL.
17. Zafar M, Rozentals G, Filippov G, et al. Adjunctive Perampanel in Pediatric Patients (Aged ≥ 1 to < 24 Months) with Epilepsy in Study 238: Interim Safety Parameter Data. Poster presented at: American Epilepsy Society (AES) Annual Meeting; December 3-7, 2021; Chicago, IL.

18. Popli GS, Rozentals G, Filippov G, et al. Interim Safety Data of Adjunctive Perampanel in Patients (Aged ≥ 1 to < 24 Months) with Epilepsy in Study 238: Treatment-Emergent Adverse Events (TEAEs) of Interest and Serious TEAEs Case Studies. Poster presented at: American Epilepsy Society (AES) Annual Meeting; December 3-7, 2021; Chicago, IL.
19. Leppik IE, Wechsler RT, Seo D, et al. Perampanel in Elderly Patients: An Overview of Data from Studies 307, 335, 412, 342, and 506. Poster presented at: American Epilepsy Society (AES) Annual Meeting; December 3-7, 2021; Chicago, IL.
20. Omatsu H, Watanabe T, Kira R, et al. Long-Term (52 Weeks) Evaluation of Adjunctive Perampanel on Mental Health in Pediatric Japanese Patients with Focal-Onset Seizures in Study 311. Poster presented at: American Epilepsy Society (AES) Annual Meeting; December 3-7, 2021; Chicago, IL.
21. Malhotra M, Nishida T, Lee SK, et al. Long-Term Seizure Freedom with Adjunctive Perampanel in Patients with Focal-Onset and Focal to Bilateral Tonic-Clonic Seizures: Post Hoc Analysis of Study 335 Open-Label Extension. Poster presented at: American Epilepsy Society (AES) Annual Meeting; December 3-7, 2021; Chicago, IL.
22. Ninomiya H, Kim JH, Lim SC, et al. Perampanel Plasma Concentrations and Clinical Effects Following 8-mg/day Monotherapy in Patients with Focal-Onset Seizures: Post Hoc Analysis of FREEDOM Study 342. Poster presented at: American Epilepsy Society (AES) Annual Meeting; December 3-7, 2021; Chicago, IL.
23. Kubota Y, Kim JH, Lim SC, et al. Perampanel Monotherapy for Focal-Onset Seizures: Post Hoc Analysis of Treatment-Emergent Adverse Events by Treatment Period During FREEDOM Study 342. Poster presented at: American Epilepsy Society (AES) Annual Meeting; December 3-7, 2021; Chicago, IL.
24. Yamamoto T, Lim SC, Ninomiya H, et al. Long-Term Efficacy and Safety of Perampanel Monotherapy in Patients with Newly Diagnosed/Currently Untreated Recurrent Focal-Onset Seizures: FREEDOM Study 342 Extension Phase. Poster presented at: American Epilepsy Society (AES) Annual Meeting; December 3-7, 2021; Chicago, IL.
25. Kim JH, Yamamoto T, Lim SC, et al. Long-Term Perampanel Monotherapy and Health-Related Quality of Life in Patients with Newly Diagnosed/Currently Untreated Recurrent Focal-Onset Seizures: FREEDOM Study 342 Extension Phase. Poster presented at: American Epilepsy Society (AES) Annual Meeting; December 3-7, 2021; Chicago, IL.
26. Rogin J, Samad O, Kumar D, et al. Safety of Perampanel (Monotherapy/First Adjunctive) by Titration and Maintenance Periods in Patients with Focal-Onset or Generalized Tonic-Clonic Seizures: Results from the Phase IV ELEVATE Study. Poster presented at: American Epilepsy Society (AES) Annual Meeting; December 3-7, 2021; Chicago, IL.

27. Kang JY, Samad O, Kumar D, et al. Assessment of Cognition (EpiTrack®) and Depression (Beck Depression Inventory-II) Following Perampanel (Monotherapy/First Adjunctive) in Patients with Epilepsy Enrolled in the ELEVATE Phase IV Study. Poster presented at: American Epilepsy Society (AES) Annual Meeting; December 3-7, 2021; Chicago, IL.
28. Bakerywala R, Samad O, Kumar D, et al. Use of the Columbia-Suicide Severity Rating Scale to Evaluate Suicidality Among Patients with Focal-Onset or Generalized Tonic-Clonic Seizures Enrolled onto the Perampanel ELEVATE 410 Phase IV Study. Poster presented at: American Epilepsy Society (AES) Annual Meeting; December 3-7, 2021; Chicago, IL.
29. Punia V, Samad O, Kumar D, et al. ELEVATE Study 410: Perampanel as Monotherapy or First Adjunctive Therapy in Patients with Focal-Onset Seizures or Generalized Tonic-Clonic Seizures: Analysis by Patient Age. Poster presented at: American Epilepsy Society (AES) Annual Meeting; December 3-7, 2021; Chicago, IL.
30. Klein P, Samad O, Kumar D, et al. ELEVATE Study 410: Phase IV Study of Perampanel as Monotherapy or First Adjunctive Therapy in Patients Aged ≥ 4 Years with Focal-Onset Seizures or Generalized Tonic-Clonic Seizures. Poster presented at: American Epilepsy Society (AES) Annual Meeting; December 3-7, 2021; Chicago, IL.
31. Biton V, Samad O, Kumar D, et al. ELEVATE Study 410: Phase IV Study of Perampanel as Monotherapy or First Adjunctive Therapy in Patients Aged ≥ 4 Years with Epilepsy: Quality of Life and Sleep Results. Poster presented at: American Epilepsy Society (AES) Annual Meeting; December 3-7, 2021; Chicago, IL.
32. Kim DW, Meletti S, Punia V, et al. Safety and Efficacy of Perampanel as First Adjunctive Therapy in Patients with Focal-Onset Seizures or Generalized Tonic-Clonic Seizures: Results from Studies 412, 501, and 410. Poster presented at: American Epilepsy Society (AES) Annual Meeting; December 3-7, 2021; Chicago, IL.
33. Giallonardo AT, Aguglia U, Goldman S, et al. Effect of Low-Dose (4-mg/day) Perampanel on Efficacy and Safety Outcomes from A Mirroring Clinical Practice Study of Adjunctive Perampanel in Adults and Adolescents (AMPA) with Focal-Onset Seizures. Poster presented at: American Epilepsy Society (AES) Annual Meeting; December 3-7, 2021; Chicago, IL.
34. Mecarelli O, Goldman S, Patten A, et al. Effect of Age on Efficacy and Safety Outcomes from A Mirroring Clinical Practice Study of Perampanel in Adults and Adolescents (AMPA). Poster presented at: American Epilepsy Society (AES) Annual Meeting; December 3-7, 2021; Chicago, IL.
35. Gentile A, Gennaro GD, D'Aniello A, et al. Final Results of A Mirroring Clinical Practice Study of Perampanel in Adults and Adolescents (AMPA): A Real-Life, Observational Study of Adjunctive Perampanel for Focal-Onset Seizures. Poster presented at: American Epilepsy Society (AES) Annual Meeting; December 3-7, 2021; Chicago, IL.

36. Assenza G, Gambardella A, Goldman S, et al. A Mirroring Clinical Practice Study of Perampanel in Adults and Adolescents: Assessment of the Impact of Perampanel on Quality of Life and Sleep in Patients with Focal-Onset Seizures. Poster presented at: American Epilepsy Society (AES) Annual Meeting; December 3-7, 2021; Chicago, IL.
37. Lee SK, Kim JH, Seo DW, et al. Study 505, a Post-Marketing Surveillance Study of Perampanel Film-Coated Tablets and Oral Suspension in Korean Patients: Study Design. Poster presented at: American Epilepsy Society (AES) Annual Meeting; December 3-7, 2021; Chicago, IL.
38. Wechsler RT, Coppola A, Rohatgi A, et al. Real-World Evidence on the Safety and Efficacy of Adjunctive Perampanel Across Different Geographical Regions from Three Phase IV Studies: Studies 506, 508, and 501. Poster presented at: American Epilepsy Society (AES) Annual Meeting; December 3-7, 2021; Chicago, IL.
39. Dash A, Omatsu H, Yamamoto T, et al. Efficacy and Safety of Perampanel in Asian Patients: Evaluating Data from Five Phase III or IV Studies. Poster presented at: American Epilepsy Society (AES) Annual Meeting; December 3-7, 2021; Chicago, IL.

E2730

1. Ali I, Silva J, Casillas-Espinosa P, et al. E2730, a GABA transporter-1 inhibitor, suppresses epileptic seizures in a rat model of chronic drug resistant mesial temporal lobe epilepsy. Poster presented at: American Epilepsy Society (AES) Annual Meeting; December 3-7, 2021; Chicago, IL.
2. Fukushima K, Higashiyama H, Kazuta Y, et al. Discovery of E2730, A Novel Selective Uncompetitive GAT-1 Inhibitor: In Vitro Characteristics. Poster presented at: American Epilepsy Society (AES) Annual Meeting; December 3-7, 2021; Chicago, IL.
3. Fukushima K, Higashiyama H, Kazuta Y, et al. Discovery of E2730, A Novel Selective Uncompetitive GAT-1 Inhibitor: In Vivo Characteristics. Poster presented at: American Epilepsy Society (AES) Annual Meeting; December 3-7, 2021; Chicago, IL.

IMPORTANT INFORMATION - PLEASE READ:

If you would like a full copy of the poster(s) listed above, please submit your request via www.eisaimedicalinformation.com/neurology/medicalinquiry or the Submit a Medical Inquiry Form available on our Medical Information website. Please include specific details: Product(s), Poster Number(s), Author(s), Title(s). You may also email your request to Eisai's Medical Information department at esi_medinfo@eisai.com or call 1-888-274-2378.